{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Platinum-Resistant+Squamous+Cell+Carcinoma+of+the+Head+and+Neck", "query": { "condition": "Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-08T21:20:31.249Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02554812", "title": "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Utomilumab", "type": "DRUG" }, { "name": "PF-04518600", "type": "DRUG" }, { "name": "PD 0360324", "type": "DRUG" }, { "name": "CMP-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 409, "start_date": "2015-11-09", "completion_date": "2023-03-23", "has_results": true, "last_update_posted_date": "2024-07-30", "last_synced_at": "2026-10-08T21:20:31.249Z", "location_count": 57, "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 23 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02554812" }, { "nct_id": "NCT05985655", "title": "Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Pancreatic Adenocarcinoma", "Non-small Cell Lung Cancer (NSCLC)", "Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)", "Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma", "Triple Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "GTAEXS617", "type": "DRUG" }, { "name": "SoC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 230, "start_date": "2023-07-06", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-08T21:20:31.249Z", "location_count": 6, "location_summary": "Los Angeles, California • Grand Rapids, Michigan • New York, New York + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05985655" }, { "nct_id": "NCT04244552", "title": "A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Ovarian Cancer", "Non-Small Cell Lung Cancer", "Acral Lentiginous Melanoma", "Head and Neck Squamous Cell Carcinoma", "Hepatocellular Carcinoma", "Esophageal Squamous Cell Carcinoma", "Urothelial Carcinoma", "DMMR Colorectal Cancer", "MSI-H Colorectal Cancer", "Melanoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Epithelial Ovarian Cancer", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "ATRC-101", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pegylated liposomal doxorubicin (PLD)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Atreca, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2020-02-11", "completion_date": "2023-11-01", "has_results": false, "last_update_posted_date": "2023-12-29", "last_synced_at": "2026-10-08T21:20:31.249Z", "location_count": 19, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04244552" }, { "nct_id": "NCT06242470", "title": "A Study of MGC026 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Advanced Cancer", "Metastatic Cancer", "Squamous Cell Carcinoma of Head and Neck", "Non Small Cell Lung Cancer", "Small-cell Lung Cancer", "Bladder Cancer", "Sarcoma", "Endometrial Cancer", "Melanoma", "Castration Resistant Prostatic Cancer", "Cervical Cancer", "Colorectal Cancer", "Gastric Cancer", "Gastro-esophageal Cancer", "Pancreas Cancer", "Clear Cell Renal Cell Carcinoma", "Hepatocellular Carcinoma", "Platinum-resistant Ovarian Cancer", "Breast Cancer", "Ovarian Cancer", "Esophageal Squamous Cell Cancer (SCC)" ], "interventions": [ { "name": "MGC026 Dose Escalation", "type": "BIOLOGICAL" }, { "name": "MGC026 Dose for Expansion", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2024-03-06", "completion_date": "2028-10", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-08T21:20:31.249Z", "location_count": 7, "location_summary": "Los Angeles, California • Grand Rapids, Michigan • Lake Success, New York + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Lake Success", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06242470" }, { "nct_id": "NCT05914116", "title": "A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "DB-1311", "type": "DRUG" }, { "name": "Lopinavir and Ritonavir Tablets", "type": "DRUG" }, { "name": "itraconazole", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DualityBio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 862, "start_date": "2023-08-17", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2025-11-21", "last_synced_at": "2026-10-08T21:20:31.249Z", "location_count": 28, "location_summary": "Tucson, Arizona • Los Angeles, California • Santa Monica, California + 21 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05914116" }, { "nct_id": "NCT01602315", "title": "A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Head and Neck Squamous Cell Carcinoma", "Metastatic Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "BYL719 as film-coated (FC) whole tablets", "type": "DRUG" }, { "name": "BYL719 as dispersible tablets (DT)", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "BYL719 drink suspension", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 179, "start_date": "2012-11-12", "completion_date": "2016-09-16", "has_results": true, "last_update_posted_date": "2020-12-29", "last_synced_at": "2026-10-08T21:20:31.249Z", "location_count": 14, "location_summary": "Sacramento, California • San Francisco, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01602315" }, { "nct_id": "NCT01332266", "title": "E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "E7050", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2011-09-19", "completion_date": "2017-09-04", "has_results": true, "last_update_posted_date": "2022-01-03", "last_synced_at": "2026-10-08T21:20:31.249Z", "location_count": 7, "location_summary": "Tucson, Arizona • Fort Myers, Florida • Boston, Massachusetts + 4 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Toledo", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01332266" }, { "nct_id": "NCT06526819", "title": "SMP-3124LP in Adults With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "SMP3124LP", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2024-08-14", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-08T21:20:31.249Z", "location_count": 11, "location_summary": "Los Angeles, California • San Francisco, California • Denver, Colorado + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Celebration", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06526819" }, { "nct_id": "NCT06084481", "title": "Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Biliary Tract Cancers", "Esophageal Squamous Cell Carcinoma", "Triple Negative Breast Cancer", "Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer", "Head and Neck Squamous-Cell Carcinoma", "Platinum Resistant High Grade Epithelial Ovarian Cancer" ], "interventions": [ { "name": "ABBV-400", "type": "DRUG" }, { "name": "Itraconazole (ITZ)", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 325, "start_date": "2023-11-09", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-08T21:20:31.249Z", "location_count": 20, "location_summary": "Duarte, California • San Francisco, California • Aurora, Colorado + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06084481" }, { "nct_id": "NCT01807546", "title": "Oral Rigosertib for Squamous Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Anal Squamous Cell Carcinoma", "Lung Squamous Cell Carcinoma", "Cervical Squamous Cell Carcinoma", "Esophageal Squamous Cell Carcinoma", "Skin Squamous Cell Carcinoma", "Penile Squamous Cell Carcinoma" ], "interventions": [ { "name": "rigosertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Traws Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2013-03", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2017-06-26", "last_synced_at": "2026-10-08T21:20:31.249Z", "location_count": 13, "location_summary": "Sacramento, California • Stanford, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01807546" } ] }